REZUROCK

sanofi-aventis canada inc🇨🇦 Health Canada

Approval Id: ef3f2a03c18007fe
Drug Approval Canada Name: REZUROCK
Product Name: REZUROCK
Status: Marketed
Status Date: 2023-03-08
Original Market Date: 2023-03-08
Din: 02526115
Drug Class: Human
Dosage Form: Tablet
Route Of Administration: Oral
Schedule: Prescription
Ahfs: 92:92.00
Atc Original: L04AA48 BELUMOSUDIL
Atc Name: l 04 aa 48
Aig Number: 0163502001
Company Name: sanofi-aventis canada inc
Company Address: 1755 Steeles Avenue West, Toronto, Ontario, Canada, M2R 3T4

BELUMOSUDIL (BELUMOSUDIL MESYLATE)

200 MG

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

ef3f2a03c18007fe

Type

Standard